12 results about "Isolated heart" patented technology

The application discloses an ex vivo heart perfusion system and a perfusion control method, wherein the perfusion system comprises: an organ bin, which is externally provided with a constant temperature heating film for controlling the temperature in the organ bin to be a first preset temperature threshold; a liquid storage container for containing a perfusion medium, an outlet end of the liquid storage container being connected to a first active branch vein through a first liquid supply pipe and connected to a pulmonary vein through a second liquid supply pipe, an inlet end of the liquid storage container being connected to a second active branch vein through a first liquid return pipe and connected to a pulmonary artery through a second liquid return pipe; a circulating pump connected to the first liquid supply pipe; an oxygenator connected to the first liquid supply pipe, the oxygenator being connected with a gas supply module for adjusting the gas mixing ratio in the perfusion medium; and an injection pump group for supplementing injection of nutrient substances or therapeutic drugs. The application can effectively prolong the heart supply storage time, reduce the heart supply discard rate, and further improve the utilization rate of the heart supply.

The invention relates to the technical field of medical image processing and artificial intelligence analysis, in particular to a mechanical perfusion heart coronary artery recognition and flow velocity estimation method based on laser speckle imaging, and is suitable for donor heart function evaluation and organ quality screening before heart transplantation. Comprising the following steps: continuously imaging the surface of an isolated heart in a mechanical perfusion state to acquire a dynamic speckle image sequence, inputting the dynamic speckle image sequence into a wavelet enhancement nnU-Net model to generate a coronary artery segmentation mask, and applying the coronary artery segmentation mask to the dynamic speckle image sequence to extract image data only containing a coronary artery region, and then generating a blood flow index map, analyzing the periodic change of the blood flow index in the coronary artery region to construct a blood flow velocity change curve, and estimating the hemodynamic parameters of the coronary artery. According to the application, automatic coronary artery identification and quantitative estimation of the blood flow velocity can be carried out on the mechanically perfused isolated heart, so that rapid and accurate non-invasive evaluation on the coronary artery system of the donor heart before heart transplantation is realized.

The application discloses a kind of for preventing or treating post myocardial infarction ventricular arrhythmia pharmaceutical composition, the pharmaceutical composition is by everolimus, ethmolam and fluoxetine, belongs to the field of medicine technology.Immunoblotting proves that everolimus, ethmolam and fluoxetine can inhibit fatty acid oxidation protein.In vitro and in vitro cardiac electrophysiology experiment proves that the pharmaceutical composition can effectively reduce post myocardial infarction ventricular arrhythmia susceptibility.TTC staining proves that the pharmaceutical composition can effectively reduce post myocardial infarction myocardial damage area.Based on the above composition in the regulation of post myocardial infarction ventricular arrhythmia susceptibility, it can be further developed in the clinical application of the disease.

The invention discloses an isolated heart transfer box and a using method thereof. The isolated heart transfer box comprises an outer box, an elastic mechanism, an inner box, a temperature adjusting module and a fixing mechanism. The inner box is arranged in the outer box, the bottom end of the inner box is connected with the inner bottom end of the outer box through the elastic mechanism, the elastic mechanism comprises a movable box, a movable block, a spring, a movable groove, a limiting plate, an ejector rod and other assemblies, under mutual cooperation, the inner box can be pressed, the elastic mechanism drives the inner box to move upwards, and the top end of the inner box extends to the outer top end of the outer box; a fixing mechanism capable of fixing the heart is arranged at the inner end of the inner box and comprises a fixing rod, a rotating sleeve, a linkage mechanism, a turbine, a driving motor and other assemblies, and the fixing rod, the rotating sleeve, the linkage mechanism, the turbine, the driving motor and other assemblies are matched with one another to clamp and fix a container for containing the heart, so that the situation that in the transportation process, the heart is damaged is avoided; heart damage caused by displacement and collision affects activity and normal use of the heart.

This invention provides a modeling device and method for simulating myocardial ischemia-reperfusion injury in an isolated heart, applicable to the field of data processing. This application aims to model ischemia-reperfusion injury in an isolated heart. First, it collects multi-source core data, including samples, perfusion data, environmental data, and physiological monitoring. Utilizing an isothermal perfusion and oxygen partial pressure regulation system, it completes cardiac rewarming, cannulation, and stable perfusion, simultaneously monitoring key indicators such as heart rate, coronary blood flow, and ventricular pressure. Ischemia and reperfusion parameters are integrated to form a basic perfusion dataset. The dataset is hierarchically structured according to physiological indicators and environmental parameters, constructing ternary association nodes for samples, indicators, and parameters. A dynamic physiological association graph is generated through temporal matching and aggregation. Core features are extracted through injury assessment and temporal prediction, generating high-dimensional vectors. These vectors are imported into an adaptive engine for iterative optimization, combined with deviation visualization to form a basic modeling model, outputting modeling information applicable to simulating ischemia-reperfusion injury in an isolated heart.

1. Name of the product in this design: Electro-gauge thermometer for blood perfusion cardiac transporter. 2. Purpose of this design: for ambient temperature mechanical perfusion of ex vivo hearts during preservation, transportation and final implantation into patients. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention discloses an in-vitro heart repair system and method. Relates to the technical field of medical instruments, in particular to an in-vitro heart repair system which comprises a perfusion container used for containing and being connected with a perfused in-vitro heart. The pipeline connecting unit is used for connecting the perfusion container with the common carotid artery and the external jugular vein of a receptor animal to form a complete extracorporeal circulation loop; the circulating power unit is arranged on the pipeline connecting unit and is used for driving blood to circulate between the isolated heart in the perfusion container and the acceptor animal; and the detection unit is used for detecting the isolated heart and determining the state of the isolated heart according to the detection result. The in-vivo physiological internal environment can be replicated, and the myocardial cell repairing efficiency is improved.

This invention relates to the field of signal denoising, specifically to a method for denoising detection signals from mechanically perfused isolated hearts based on dual-domain transform. The method first decomposes the original detection signal from the isolated heart under mechanical perfusion conditions into multiple signal components. Based on spectral kurtosis, the signal components characterizing fluid noise are removed. A preliminary denoised signal is reconstructed using the retained signal components. Wavelet decomposition is then performed on the preliminary denoised signal to obtain a wavelet coefficient vector. This vector is then optimized using a constructed loss function to obtain the optimal wavelet coefficient vector for the preliminary denoised signal. Based on the optimal wavelet coefficient vector, the signal is reconstructed to obtain the denoised detection signal. This invention effectively removes noise from the detection signal while better preserving the key morphological features of the signal, thus improving the denoising quality of the isolated heart detection signal under mechanical perfusion conditions.

The present application relates to the technical field of medical devices, in particular to a multi-channel electrophysiological mapping system and method for isolated heart tissue based on a microelectrode array, wherein the system comprises: a microelectrode array for contacting and recording original electrical activity signals of excitable tissue or cells; a pressure detection module for collecting systolic and diastolic pressure of the heart tissue; an electrical signal acquisition module for filtering the original electrical signals transmitted by the microelectrode array in combination with the systolic and diastolic pressure to obtain net electrical activity signals, the electrical signal acquisition module comprising a first adaptive filter and a second adaptive filter, the first adaptive filter being used for motion artifact filtering of the original electrical signals according to the systolic and diastolic pressure of the heart tissue, and the second adaptive filter being used for series mode interference filtering of the original electrical signals. The above-mentioned system innovatively filters in combination with the systolic and diastolic pressure signals, effectively improving the signal-to-noise ratio and quality of the net electrical activity signals.

The invention discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial infarction, and belongs to the technical field of medicines. The pharmaceutical composition is prepared from everolimus, etomadectin and fluoxetine. Western blot proves that everolimus, etomadectin and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro cardiac electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the ventricular arrhythmia susceptibility after myocardial infarction. TTC dyeing proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial infarction. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial infarction, the clinical application of the composition to the ventricular arrhythmia after myocardial infarction can be further developed.

The invention belongs to the technical field of medicines, and discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial ischemia-reperfusion, the pharmaceutical composition is composed of diosmin, etomoxazide and fluoxetine, and the mass ratio of diosmin to etomoxazide to fluoxetine is 1: 1: 1. Western blot proves that diosmin, etomagazide and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro heart electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion. TTC staining proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial ischemia reperfusion. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion, the clinical application of the composition to the ventricular arrhythmia after myocardial ischemia-reperfusion can be further developed.

This invention discloses a method for extracting interstitial fluid from cardiac tissue, belonging to the field of biomedical technology. Based on the unique characteristics of the heart, a organ closely related to blood circulation, and its differences in tissue physical properties compared to other organs, this invention designs and develops this extraction method, which specifically includes: rinsing isolated cardiac tissue with pre-cooled physiological saline; low-speed centrifugation to remove residual rinsing fluid from the heart; and centrifugation again to obtain interstitial fluid from the cardiac tissue. Comparison of the obtained interstitial fluid with cardiac cell fluid and serum confirms the accuracy and specificity of the extraction scheme of this invention. The centrifugation process of this invention does not damage cells, preserving its unique differences from serum and cardiac cell fluid. The extracted interstitial fluid has a high protein concentration, which can better reflect changes in the cardiac microenvironment, facilitating subsequent related medical and basic research.